How can I address stability testing for orphan drug products with limited data?
Addressing Stability Testing for Orphan Drug Products with Limited Data Stability testing for orphan drug products with limited data presents unique challenges due to the scarcity of available information. However, regulatory agencies recognize the importance of ensuring the quality, safety, and efficacy of these specialized products. In this discussion, I’ll outline strategies for addressing stability…
Read More “How can I address stability testing for orphan drug products with limited data?” »